Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mediators Inflamm ; 2009: 932515, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19365587

RESUMO

We investigated the effects of clopidogrel on reperfusion and inflammatory process in STEMI. A total of 175 STEMI patients with similar clinical characteristics were included to this study. One was the standard pharmacological reperfusion therapy group (group 1, n : 90), who received 300 mg aspirin, 70 U/kg bolus, and 12 U/kg/hr continuous infusion of unfractioned heparin and accelerated t-PA. Clopidogrel 450 mg loading and 75 mg/d thereafter was added to standard reperfusion therapy in the other group (group 2, n : 85). The ST-segment resolution, CK-MB, and high-sensitive CRP (hs-CRP) parameters were measured. Complete ST resolution was observed in 32 patients (36.8%) in group 1 and 53 patients (63.8%) in group 2 (P < .001). Also in the first 24 hours, the CK-MB levels of patients in group 1 were significantly higher than those of group 2 (P = .001). The hs-CRP values were greater in group 1 than group 2 at 48th hour (group 1: 9.4 +/- 0.1 mg/L, group 2: 3.7 +/- 1.4 mg/L; P = .000). We concluded that adding clopidogrel to standard treatment in STEMI patients provided early reperfusion and suppression of inflammatory response.


Assuntos
Proteína C-Reativa/metabolismo , Circulação Coronária/efeitos dos fármacos , Infarto do Miocárdio/fisiopatologia , Infarto do Miocárdio/terapia , Reperfusão Miocárdica , Inibidores da Agregação Plaquetária/uso terapêutico , Ticlopidina/análogos & derivados , Aspirina/uso terapêutico , Clopidogrel , Creatina Quinase Forma MB/sangue , Quimioterapia Combinada , Eletrocardiografia , Feminino , Fibrinolíticos/uso terapêutico , Heparina/uso terapêutico , Humanos , Inflamação/prevenção & controle , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Reperfusão Miocárdica/métodos , Ticlopidina/uso terapêutico , Fatores de Tempo , Ativador de Plasminogênio Tecidual/uso terapêutico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA